Obsidian Therapeutics Inc.
A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein…
1D
-3.5%
1W
-9.5%
1M
-31.4%
6M
–
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
No date known
Volatility around earnings
~61% weaker price swings than usual
PRICE TARGET LOW
US$32.00
CONSENSUS
US$37.00
MEDIAN
US$37.00
PRICE TARGET HIGH
US$42.00
No current analyst ratings available.
FREE FLOAT
–
FLOAT SHARES
493,493
AVG. DAILY VOLUME (30D)
607,998
Obsidian Therapeutics Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Madan Jagasia, the company employs around 87 people.
The IPO was on 04/08/2026; the stock trades on NASDAQ under the ticker OBX.
The average price target is US$37.00, ranging from US$32.00 to US$42.00, with a median of US$37.00.
This is an external assessment, not a statement by Market Jury.
Around past earnings, price swings were roughly -61% stronger than usual.
No, Obsidian Therapeutics currently does not pay a dividend.
Clicking "Analyze stock" lets five strategies assess Obsidian Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.